vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 24.6% in March

vTv Therapeutics Inc. (NASDAQ:VTVT) saw a significant increase in short interest in March. As of March 31st, there was short interest totaling 82,236 shares, an increase of 24.6% from the March 15th total of 65,987 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average daily volume of 46,188 shares, the days-to-cover ratio is currently 1.8 days.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Wall Street Zen raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Friday, March 27th. BTIG Research reissued a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, March 11th. TD Cowen began coverage on shares of vTv Therapeutics in a report on Monday, January 5th. They set a “buy” rating on the stock. Finally, Roth Mkm began coverage on shares of vTv Therapeutics in a report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $53.00.

Institutional Trading of vTv Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. purchased a new stake in shares of vTv Therapeutics during the 4th quarter worth about $221,000. 683 Capital Management LLC acquired a new position in shares of vTv Therapeutics in the 4th quarter valued at approximately $731,000. Geode Capital Management LLC raised its position in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares in the last quarter. Finally, Baker BROS. Advisors LP raised its position in shares of vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after purchasing an additional 51,000 shares in the last quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Stock Up 3.7%

Shares of NASDAQ:VTVT opened at $38.12 on Friday. The stock has a market cap of $150.19 million, a price-to-earnings ratio of -11.38 and a beta of 0.40. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The firm’s 50 day moving average price is $36.82 and its 200 day moving average price is $32.57.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.51.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.